The "U.S. Prostate Cancer Treatment Device Market Research Report: By Type (Radiation, Surgery, High-Intensity Focused Ultrasound, Cryotherapy), End User (Hospitals, Specialty Centers) - Industry Analysis and Growth Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
The U.S. prostate cancer treatment devices market attained a value of $95.9 million in 2019 and is predicted to grow at a CAGR of 5.6% between 2020 and 2030, to reach a valuation of $157.1 million.
The main factors driving the progress of the market are the increasing number of prostate cancer cases being recorded in the country every year.
The high prevalence of this diseases is predicted to push up the demand for various treatment devices and equipment such as cryotherapy, surgery, and radiotherapy in the future years, thereby causing the expansion of the U.S. prostate cancer treatment devices market. Apart from this, the increasing number of government initiatives being implemented in the country is also fueling the market advancement. The federal government spends a huge portion of the country's GDP on healthcare every year.
As per the reports of the National Health Expenditure Accounts (NHEA), healthcare expenditure in the U.S. increased by as much as 4.3% and reached $3.3 trillion in 2016. This percentage further grew to 5.4% in 2017. The soaring healthcare expenditure is making the management and treatment of various diseases more affordable than they were before, which is, in turn, fueling the expansion of the U.S. prostate cancer treatment devices market.
Thus, it can be said with certainty that the market would demonstrate substantial growth in the upcoming years, mainly because of the rising incidence of prostate cancer and the surging government spending on healthcare in the country.
Key Topics Covered:
Chapter 1. Research Background
Chapter 2. Research Methodology
Chapter 3. Executive Summary
Chapter 4. Introduction
4.1 Definition of Market Segments
4.1.1 By Type
188.8.131.52.1 Clinical trials
184.108.40.206.1 Clinical trials
220.127.116.11.1 Clinical trials
18.104.22.168.1 Clinical trials
4.1.2 By End User
22.214.171.124 Specialty centers
4.2 Market Dynamics
126.96.36.199 Adoption of robotic prostatectomy
188.8.131.52 Accelerating evolution in radiotherapy techniques
184.108.40.206 Technological advancements
220.127.116.11 Increasing prevalence of prostate cancer
18.104.22.168 Rising number of government initiatives
22.214.171.124 Surging geriatric population
126.96.36.199 Impact analysis of drivers on market forecast
188.8.131.52 Longer approval time for prostate cancer devices
184.108.40.206 Challenges in identifying molecular predictors of response to radiotherapy
220.127.116.11 Impact analysis of drivers on market forecast
18.104.22.168 Positioning devices to improve treatment and patient experience
4.3 COVID-19 Impact on U.S. Prostate Cancer Treatment Devices Market
4.3.1 Supply Side Analysis
4.3.2 Demand Side Analysis
4.4 Porter's Five Forces Analysis
4.5 Therapy Comparison
4.5.1 HIFU Therapy
4.5.2 Surgery Vs Radiation Therapy
4.6 Average Pricing of Devices
Chapter 5. U.S. Market Size and Forecast
5.1 By Type
5.2 By End User
5.3 By State
Chapter 6. Competitive Landscape
6.1 Product Benchmarking of Key Players
6.2 Strategic Developments of Key Players
6.2.1 Approvals and Product Launch
6.2.2 Mergers and Acquisitions
6.2.3 Other Developments
Chapter 7. Company Profiles
SonaCare Medical LLC
EDAP TMS SA
Profound Medical Corporation
Eckert & Ziegler AG
Boston Scientific Corporation
Varian Medical Systems Inc.
Becton, Dickinson and Company
Intuitive Surgical Inc.
For more information about this report visit https://www.researchandmarkets.com/r/5v2f5u
View source version on businesswire.com: https://www.businesswire.com/news/home/20201126005577/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900